WEDNESDAY, June 25, 2025 (HealthDay News) — The oral small-molecule glucagon-like peptide-1 receptor agonist, orforglipron, reduced glycated hemoglobin (HbA1c) over 40 weeks in adults with early type 2 diabetes, according […]
The post ADA: Orforglipron Reduces Glycated Hemoglobin in Early Type 2 Diabetes first appeared on Blackandmed .
